| Views | |
|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 214 |
| January 2025 | February 2025 | March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | |
|---|---|---|---|---|---|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 11 | 8 | 4 | 21 | 1 | 7 | 0 |
| Views | |
|---|---|
| 2021_Frost_etal.pdf | 248 |
